Junlin  Ho net worth and biography

Junlin Ho Biography and Net Worth

General Counsel & Corporate Secretary of Scholar Rock

Junlin Ho joined Scholar Rock in 2018 and has served as General Counsel & Corporate Secretary since February 2021, overseeing all legal affairs, including corporate governance, compliance, and intellectual property. She has over 15 years of experience leading and advising life sciences companies on various legal aspects associated with corporate governance, business development, financing, securities law, commercial product planning and launches, and international operations. Prior to Scholar Rock, she served as Associate General Counsel at Foundation Medicine where she helped lead the team in support of that company’s initial public offering and was a member of the team that negotiated a major strategic partnership. Additionally, Junlin served as Associate General Counsel, Corporate at Ziopharm Oncology and was a corporate attorney in the life sciences practice at the law firm Ropes & Gray LLP. She received her J.D. from the University of Chicago Law School and a B.S. from the Massachusetts Institute of Technology.

What is Junlin Ho's net worth?

The estimated net worth of Junlin Ho is at least $8.56 million as of February 18th, 2025. Ms. Ho owns 189,295 shares of Scholar Rock stock worth more than $8,556,134 as of December 4th. This net worth estimate does not reflect any other investments that Ms. Ho may own. Additionally, Ms. Ho receives a salary of $563,730.00 as General Counsel & Corporate Secretary at Scholar Rock. Learn More about Junlin Ho's net worth.

How old is Junlin Ho?

Ms. Ho is currently 45 years old. There are 6 older executives and no younger executives at Scholar Rock. The oldest executive at Scholar Rock is Dr. Jay Thomas Backstrom M.D., M.P.H., President, CEO & Director, who is 69 years old. Learn More on Junlin Ho's age.

What is Junlin Ho's salary?

As the General Counsel & Corporate Secretary of Scholar Rock Holding Corporation, Ms. Ho earns $563,730.00 per year. There are 2 executives that earn more than Ms. Ho. The highest earning executive at Scholar Rock is Dr. Jay Thomas Backstrom M.D., M.P.H., President, CEO & Director, who commands a salary of $1,070,000.00 per year. Learn More on Junlin Ho's salary.

How do I contact Junlin Ho?

The corporate mailing address for Ms. Ho and other Scholar Rock executives is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. Scholar Rock can also be reached via phone at (857) 259-3860 and via email at [email protected]. Learn More on Junlin Ho's contact information.

Has Junlin Ho been buying or selling shares of Scholar Rock?

Junlin Ho has not been actively trading shares of Scholar Rock during the last ninety days. Most recently, Junlin Ho sold 5,742 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $36.83, for a transaction totalling $211,477.86. Following the completion of the sale, the general counsel now directly owns 189,295 shares of the company's stock, valued at $6,971,734.85. Learn More on Junlin Ho's trading history.

Who are Scholar Rock's active insiders?

Scholar Rock's insider roster includes Srinivas Akkaraju (Director), Jay Backstrom (President & CEO), Kristina Burow (Director), Jeffrey Flier (Director), Michael Gilman (Director), Junlin Ho (General Counsel & Corporate Secretary), Jing Marantz (Chief Medical Officer), Edward Myles (CFO), Caryn Parlavecchio (Insider), Katie Peng (Chief Commercial Officer, Denali Therapeutics), Mo Qatanani (Insider), Joshua Reed (Director), Tracey Sacco (Chief Commercial Officer), and Akshay Vaishnaw (President, R&D). Learn More on Scholar Rock's active insiders.

Are insiders buying or selling shares of Scholar Rock?

In the last year, Scholar Rock insiders bought shares 2 times. They purchased a total of 500,439 shares worth more than $18,807,336.03. In the last year, insiders at the sold shares 24 times. They sold a total of 405,963 shares worth more than $14,753,847.01. The most recent insider tranaction occured on October, 6th when Director Srinivas Akkaraju bought 113,025 shares worth more than $4,368,416.25. Insiders at Scholar Rock own 13.3% of the company. Learn More about insider trades at Scholar Rock.

Information on this page was last updated on 10/6/2025.

Junlin Ho Insider Trading History at Scholar Rock

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/18/2025Sell5,742$36.83$211,477.86189,295View SEC Filing Icon  
1/16/2025Sell9,039$44.20$399,523.80195,037View SEC Filing Icon  
6/17/2024Sell4,695$8.98$42,161.10204,076View SEC Filing Icon  
2/16/2024Sell3,489$15.74$54,916.86208,771View SEC Filing Icon  
See Full Table

Junlin Ho Buying and Selling Activity at Scholar Rock

This chart shows Junlin Ho's buying and selling at Scholar Rock by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Scholar Rock Company Overview

Scholar Rock logo
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $45.20
Low: $42.83
High: $45.50

50 Day Range

MA: $34.97
Low: $27.92
High: $45.20

2 Week Range

Now: $45.20
Low: $22.71
High: $46.98

Volume

1,340,235 shs

Average Volume

2,069,553 shs

Market Capitalization

$4.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61